Pharmaceutical Stability And Storage Services Market Size, Share & Trends Analysis Report By Service (Stability, Storage), By Molecule (Large Molecule, Small Molecule), By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 2 Business Days
Pharmaceutical Inspection Machines Market Growth & Trends
The global pharmaceutical inspection machines market is anticipated to reach USD 1.62 billion by 2030, growing at a CAGR of 9.9%, according to a report by Grand View Research, Inc. This growth trajectory is driven by several critical factors, including the increasing prevalence of chronic and complex diseases, stringent regulatory requirements, technological advancements, and expanding pharmaceutical outsourcing. As the industry evolves, stakeholders are increasingly investing in advanced inspection systems to ensure product quality, meet regulatory standards, and address the complexities of modern drug formulations.
The growing prevalence of chronic diseases and complex drug formulations significantly drives the demand for sophisticated inspection technologies. As treatments for conditions such as cancer, diabetes, and cardiovascular diseases evolve, there is a corresponding need for advanced inspection systems capable of handling new drug formulations and biologics. These include large molecules like monoclonal antibodies and gene therapies, which require high-precision inspection to ensure efficacy and safety.
Innovations in artificial intelligence (AI) and machine learning (ML) have transformed inspection systems, enhancing their accuracy and efficiency. AI-powered vision systems can now detect minute defects in real time with high resolution, which is crucial for complex drug formulations and biologics. For instance, integrating AI into inspection machines, such as those by Syntegon Technology, allows for real-time defect detection and higher detection rates, improving overall product quality and compliance.
Pharmaceutical Inspection Machines Market Report Highlights
Pharmaceutical Inspection Machines Market Growth & Trends
The global pharmaceutical inspection machines market is anticipated to reach USD 1.62 billion by 2030, growing at a CAGR of 9.9%, according to a report by Grand View Research, Inc. This growth trajectory is driven by several critical factors, including the increasing prevalence of chronic and complex diseases, stringent regulatory requirements, technological advancements, and expanding pharmaceutical outsourcing. As the industry evolves, stakeholders are increasingly investing in advanced inspection systems to ensure product quality, meet regulatory standards, and address the complexities of modern drug formulations.
The growing prevalence of chronic diseases and complex drug formulations significantly drives the demand for sophisticated inspection technologies. As treatments for conditions such as cancer, diabetes, and cardiovascular diseases evolve, there is a corresponding need for advanced inspection systems capable of handling new drug formulations and biologics. These include large molecules like monoclonal antibodies and gene therapies, which require high-precision inspection to ensure efficacy and safety.
Innovations in artificial intelligence (AI) and machine learning (ML) have transformed inspection systems, enhancing their accuracy and efficiency. AI-powered vision systems can now detect minute defects in real time with high resolution, which is crucial for complex drug formulations and biologics. For instance, integrating AI into inspection machines, such as those by Syntegon Technology, allows for real-time defect detection and higher detection rates, improving overall product quality and compliance.
Pharmaceutical Inspection Machines Market Report Highlights
- Based on component, the inspection systems segment dominated the market with a substantial share of 76.0% in 2023 and is also expected to grow at the fastest CAGR of 10.2% during the forecast period. This segment's substantial market share and rapid growth can be attributed to the increasing complexity of pharmaceutical products, stringent regulatory requirements, and ongoing technological advancements.
- Based on type, the fully automated segment held the largest revenue share of more than 40.0% in 2023 and is also expected to grow at the fastest CAGR of 10.5% during the forecast period.
- Based on formulation, the oral segment dominated the global market for pharmaceutical inspection machines in 2023, capturing a substantial revenue share and is also expected to growth at the fastest CAGR during the forecast period. This prominence is primarily driven by the high demand for oral medications and stringent regulatory standards.
- Based on end use, the syringes segment dominated the global market in 2023, capturing a substantial revenue share of 35.8%.
- CROs & CDMOs are anticipated to achieve the fastest CAGR of 10.2% during the forecast period.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity Flow Analysis
1.6.2. Bottom-up Approach
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. PHARMACEUTICAL STABILITY & STORAGE SERVICES VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High R&D Spending of Pharmaceutical & Biotechnology Companies
3.2.1.2. Growing Demand for Outsourcing Stability Testing Due to High Complexity Associated with Drug Stability
3.2.1.3. Growing Demand for Biosimilars
3.2.1.4. Growing Outsourcing Trend in the Market
3.2.2. Market restraint analysis
3.2.2.1. Strict Regulations for Global Pharmaceutical Stability and Storage Services Drugs
3.2.2.2. Issues Associated with Stability Chambers
3.3. Cost Structure of Stability and Storage
3.4. Pharmaceutical Stability & Storage Services Analysis Tools
3.4.1. Porter’s Five Forces Analysis
3.4.2. PESTEL Analysis
CHAPTER 4. PHARMACEUTICAL STABILITY & STORAGE SERVICES MARKET: SERVICE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Global Pharmaceutical Stability & Storage Services Market; Service Movement Analysis
4.3. Global Pharmaceutical Stability & Storage Services Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
4.4. Stability
4.4.1. Stability market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Drug Substance
4.4.2.1. Drug substance market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Stability Indicating Method Validation
4.4.3.1. Stability indicating method validation market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Accelerated Stability Testing
4.4.4.1. Accelerated stability testing market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Photostability Testing
4.4.5.1. Photostability testing market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6. Other Stability Testing Methods
4.4.6.1. Other stability testing methods market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Storage
4.5.1. Storage market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2. Cold
4.5.2.1. Cold market estimates and forecasts 2018 to 2030 (USD Million)
4.5.3. Non-cold
4.5.3.1. Non-cold market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. PHARMACEUTICAL STABILITY & STORAGE SERVICES MARKET: MOLECULE ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Global Pharmaceutical Stability & Storage Services Market; Molecule Movement Analysis
5.3. Global Pharmaceutical Stability & Storage Services Size & Trend Analysis, by Molecule, 2018 to 2030 (USD Million)
5.4. Small Molecule
5.4.1. Small molecule market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Research Products
5.4.2.1. Research products market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Commercial Products
5.4.3.1. Commercial products market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Large Molecule
5.5.1. Large molecule market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2. Research Products
5.5.2.1. Research products market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3. Commercial Products
5.5.3.1. Commercial products market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. PHARMACEUTICAL STABILITY & STORAGE SERVICES MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional Market Share Analysis, 2023 & 2030
6.2. Regional Market Dashboard
6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key country dynamics
6.4.2.2. Competitive scenario
6.4.2.3. Regulatory framework
6.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key country dynamics
6.4.3.2. Competitive scenario
6.4.3.3. Regulatory framework
6.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key country dynamics
6.4.4.2. Competitive scenario
6.4.4.3. Regulatory framework
6.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Europe
6.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.2. UK
6.5.2.1. Key country dynamics
6.5.2.2. Competitive scenario
6.5.2.3. Regulatory framework
6.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key country dynamics
6.5.3.2. Competitive scenario
6.5.3.3. Regulatory framework
6.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. France
6.5.4.1. Key country dynamics
6.5.4.2. Competitive scenario
6.5.4.3. Regulatory framework
6.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key country dynamics
6.5.5.2. Competitive scenario
6.5.5.3. Regulatory framework
6.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key country dynamics
6.5.6.2. Competitive scenario
6.5.6.3. Regulatory framework
6.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.5.7. Denmark
6.5.7.1. Key country dynamics
6.5.7.2. Competitive scenario
6.5.7.3. Regulatory framework
6.5.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.5.8. Sweden
6.5.8.1. Key country dynamics
6.5.8.2. Competitive scenario
6.5.8.3. Regulatory framework
6.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.5.9. Norway
6.5.9.1. Key country dynamics
6.5.9.2. Competitive scenario
6.5.9.3. Regulatory framework
6.5.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key country dynamics
6.6.2.2. Competitive scenario
6.6.2.3. Regulatory framework
6.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. China
6.6.3.1. Key country dynamics
6.6.3.2. Competitive scenario
6.6.3.3. Regulatory framework
6.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. India
6.6.4.1. Key country dynamics
6.6.4.2. Competitive scenario
6.6.4.3. Regulatory framework
6.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. Australia
6.6.5.1. Key country dynamics
6.6.5.2. Competitive scenario
6.6.5.3. Regulatory framework
6.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. South Korea
6.6.6.1. Key country dynamics
6.6.6.2. Competitive scenario
6.6.6.3. Regulatory framework
6.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key country dynamics
6.6.7.2. Competitive scenario
6.6.7.3. Regulatory framework
6.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key country dynamics
6.7.2.2. Competitive scenario
6.7.2.3. Regulatory framework
6.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key country dynamics
6.7.3.2. Competitive scenario
6.7.3.3. Regulatory framework
6.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.8. MEA
6.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key country dynamics
6.8.2.2. Competitive scenario
6.8.2.3. Regulatory framework
6.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key country dynamics
6.8.3.2. Competitive scenario
6.8.3.3. Regulatory framework
6.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key country dynamics
6.8.4.2. Competitive scenario
6.8.4.3. Regulatory framework
6.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key country dynamics
6.8.5.2. Competitive scenario
6.8.5.3. Regulatory framework
6.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Company Categorization
7.2. Company Market Position Analysis, 2023
7.3. Company Profiles
7.3.1. Catalent, Inc
7.3.1.1. Company overview
7.3.1.2. Financial performance
7.3.1.3. Service benchmarking
7.3.1.4. Strategic initiatives
7.3.2. Almac Group
7.3.2.1. Company overview
7.3.2.2. Financial performance
7.3.2.3. Service benchmarking
7.3.2.4. Strategic initiatives
7.3.3. Charles River Laboratories
7.3.3.1. Company overview
7.3.3.2. Financial performance
7.3.3.3. Service benchmarking
7.3.3.4. Strategic initiatives
7.3.4. SGS Sociйtй Gйnйrale de Surveillance SA.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Service benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Eurofins Scientific
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Service benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Intertek Group plc
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Service benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Lucideon Limited
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Service benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Alcami Corporation
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Service benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Element Materials Technology
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Service benchmarking
7.3.9.4. Strategic initiatives
7.3.10. BioLife Solutions Inc.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Service benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Q1 Scientific
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Service benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Reading Scientific Services Ltd.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Service benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Roylance Stability Storage Limited
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Service benchmarking
7.3.13.4. Strategic initiatives
7.3.14. ALS
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Service benchmarking
7.3.14.4. Strategic initiatives
7.3.15. Q Laboratories
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Service benchmarking
7.3.15.4. Strategic initiatives
7.3.16. Auriga Research Private Limited
7.3.16.1. Company overview
7.3.16.2. Financial performance
7.3.16.3. Service benchmarking
7.3.16.4. Strategic initiatives
7.3.17. PD Partners
7.3.17.1. Company overview
7.3.17.2. Financial performance
7.3.17.3. Service benchmarking
7.3.17.4. Strategic initiatives
7.3.18. Precision Stability Storage
7.3.18.1. Company overview
7.3.18.2. Financial performance
7.3.18.3. Service benchmarking
7.3.18.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity Flow Analysis
1.6.2. Bottom-up Approach
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. PHARMACEUTICAL STABILITY & STORAGE SERVICES VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High R&D Spending of Pharmaceutical & Biotechnology Companies
3.2.1.2. Growing Demand for Outsourcing Stability Testing Due to High Complexity Associated with Drug Stability
3.2.1.3. Growing Demand for Biosimilars
3.2.1.4. Growing Outsourcing Trend in the Market
3.2.2. Market restraint analysis
3.2.2.1. Strict Regulations for Global Pharmaceutical Stability and Storage Services Drugs
3.2.2.2. Issues Associated with Stability Chambers
3.3. Cost Structure of Stability and Storage
3.4. Pharmaceutical Stability & Storage Services Analysis Tools
3.4.1. Porter’s Five Forces Analysis
3.4.2. PESTEL Analysis
CHAPTER 4. PHARMACEUTICAL STABILITY & STORAGE SERVICES MARKET: SERVICE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Global Pharmaceutical Stability & Storage Services Market; Service Movement Analysis
4.3. Global Pharmaceutical Stability & Storage Services Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
4.4. Stability
4.4.1. Stability market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Drug Substance
4.4.2.1. Drug substance market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Stability Indicating Method Validation
4.4.3.1. Stability indicating method validation market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Accelerated Stability Testing
4.4.4.1. Accelerated stability testing market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Photostability Testing
4.4.5.1. Photostability testing market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6. Other Stability Testing Methods
4.4.6.1. Other stability testing methods market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Storage
4.5.1. Storage market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2. Cold
4.5.2.1. Cold market estimates and forecasts 2018 to 2030 (USD Million)
4.5.3. Non-cold
4.5.3.1. Non-cold market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. PHARMACEUTICAL STABILITY & STORAGE SERVICES MARKET: MOLECULE ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. Global Pharmaceutical Stability & Storage Services Market; Molecule Movement Analysis
5.3. Global Pharmaceutical Stability & Storage Services Size & Trend Analysis, by Molecule, 2018 to 2030 (USD Million)
5.4. Small Molecule
5.4.1. Small molecule market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Research Products
5.4.2.1. Research products market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Commercial Products
5.4.3.1. Commercial products market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Large Molecule
5.5.1. Large molecule market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2. Research Products
5.5.2.1. Research products market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3. Commercial Products
5.5.3.1. Commercial products market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. PHARMACEUTICAL STABILITY & STORAGE SERVICES MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional Market Share Analysis, 2023 & 2030
6.2. Regional Market Dashboard
6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key country dynamics
6.4.2.2. Competitive scenario
6.4.2.3. Regulatory framework
6.4.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key country dynamics
6.4.3.2. Competitive scenario
6.4.3.3. Regulatory framework
6.4.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key country dynamics
6.4.4.2. Competitive scenario
6.4.4.3. Regulatory framework
6.4.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Europe
6.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.2. UK
6.5.2.1. Key country dynamics
6.5.2.2. Competitive scenario
6.5.2.3. Regulatory framework
6.5.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key country dynamics
6.5.3.2. Competitive scenario
6.5.3.3. Regulatory framework
6.5.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. France
6.5.4.1. Key country dynamics
6.5.4.2. Competitive scenario
6.5.4.3. Regulatory framework
6.5.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key country dynamics
6.5.5.2. Competitive scenario
6.5.5.3. Regulatory framework
6.5.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key country dynamics
6.5.6.2. Competitive scenario
6.5.6.3. Regulatory framework
6.5.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.5.7. Denmark
6.5.7.1. Key country dynamics
6.5.7.2. Competitive scenario
6.5.7.3. Regulatory framework
6.5.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.5.8. Sweden
6.5.8.1. Key country dynamics
6.5.8.2. Competitive scenario
6.5.8.3. Regulatory framework
6.5.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.5.9. Norway
6.5.9.1. Key country dynamics
6.5.9.2. Competitive scenario
6.5.9.3. Regulatory framework
6.5.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key country dynamics
6.6.2.2. Competitive scenario
6.6.2.3. Regulatory framework
6.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. China
6.6.3.1. Key country dynamics
6.6.3.2. Competitive scenario
6.6.3.3. Regulatory framework
6.6.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. India
6.6.4.1. Key country dynamics
6.6.4.2. Competitive scenario
6.6.4.3. Regulatory framework
6.6.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. Australia
6.6.5.1. Key country dynamics
6.6.5.2. Competitive scenario
6.6.5.3. Regulatory framework
6.6.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. South Korea
6.6.6.1. Key country dynamics
6.6.6.2. Competitive scenario
6.6.6.3. Regulatory framework
6.6.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key country dynamics
6.6.7.2. Competitive scenario
6.6.7.3. Regulatory framework
6.6.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key country dynamics
6.7.2.2. Competitive scenario
6.7.2.3. Regulatory framework
6.7.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key country dynamics
6.7.3.2. Competitive scenario
6.7.3.3. Regulatory framework
6.7.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.8. MEA
6.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key country dynamics
6.8.2.2. Competitive scenario
6.8.2.3. Regulatory framework
6.8.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key country dynamics
6.8.3.2. Competitive scenario
6.8.3.3. Regulatory framework
6.8.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key country dynamics
6.8.4.2. Competitive scenario
6.8.4.3. Regulatory framework
6.8.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key country dynamics
6.8.5.2. Competitive scenario
6.8.5.3. Regulatory framework
6.8.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Company Categorization
7.2. Company Market Position Analysis, 2023
7.3. Company Profiles
7.3.1. Catalent, Inc
7.3.1.1. Company overview
7.3.1.2. Financial performance
7.3.1.3. Service benchmarking
7.3.1.4. Strategic initiatives
7.3.2. Almac Group
7.3.2.1. Company overview
7.3.2.2. Financial performance
7.3.2.3. Service benchmarking
7.3.2.4. Strategic initiatives
7.3.3. Charles River Laboratories
7.3.3.1. Company overview
7.3.3.2. Financial performance
7.3.3.3. Service benchmarking
7.3.3.4. Strategic initiatives
7.3.4. SGS Sociйtй Gйnйrale de Surveillance SA.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Service benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Eurofins Scientific
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Service benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Intertek Group plc
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Service benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Lucideon Limited
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Service benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Alcami Corporation
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Service benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Element Materials Technology
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Service benchmarking
7.3.9.4. Strategic initiatives
7.3.10. BioLife Solutions Inc.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Service benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Q1 Scientific
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Service benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Reading Scientific Services Ltd.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Service benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Roylance Stability Storage Limited
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Service benchmarking
7.3.13.4. Strategic initiatives
7.3.14. ALS
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Service benchmarking
7.3.14.4. Strategic initiatives
7.3.15. Q Laboratories
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Service benchmarking
7.3.15.4. Strategic initiatives
7.3.16. Auriga Research Private Limited
7.3.16.1. Company overview
7.3.16.2. Financial performance
7.3.16.3. Service benchmarking
7.3.16.4. Strategic initiatives
7.3.17. PD Partners
7.3.17.1. Company overview
7.3.17.2. Financial performance
7.3.17.3. Service benchmarking
7.3.17.4. Strategic initiatives
7.3.18. Precision Stability Storage
7.3.18.1. Company overview
7.3.18.2. Financial performance
7.3.18.3. Service benchmarking
7.3.18.4. Strategic initiatives
